94 related articles for article (PubMed ID: 23300027)
1. Predicting the impact of single-nucleotide polymorphisms in CDK2-flavopiridol complex by molecular dynamics analysis.
Nagasundaram N; Doss CG
Cell Biochem Biophys; 2013 Jul; 66(3):681-95. PubMed ID: 23300027
[TBL] [Abstract][Full Text] [Related]
2. Extrapolating the effect of deleterious nsSNPs in the binding adaptability of flavopiridol with CDK7 protein: a molecular dynamics approach.
George Priya Doss C; Nagasundaram N; Chakraborty C; Chen L; Zhu H
Hum Genomics; 2013 Apr; 7(1):10. PubMed ID: 23561625
[TBL] [Abstract][Full Text] [Related]
3. Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors.
Tripathi SK; Muttineni R; Singh SK
J Theor Biol; 2013 Oct; 334():87-100. PubMed ID: 23727278
[TBL] [Abstract][Full Text] [Related]
4. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
[TBL] [Abstract][Full Text] [Related]
5. Analysing the Effect of Mutation on Protein Function and Discovering Potential Inhibitors of CDK4: Molecular Modelling and Dynamics Studies.
N N; Zhu H; Liu J; V K; C GP; Chakraborty C; Chen L
PLoS One; 2015; 10(8):e0133969. PubMed ID: 26252490
[TBL] [Abstract][Full Text] [Related]
6. Computational identification of pathogenic associated nsSNPs and its structural impact in UROD gene: a molecular dynamics approach.
Doss CG; Magesh R
Cell Biochem Biophys; 2014 Nov; 70(2):735-46. PubMed ID: 24777812
[TBL] [Abstract][Full Text] [Related]
7. A flavonoid gossypin binds to cyclin-dependent kinase 2.
Kim H; Lee E; Kim J; Jung B; Chong Y; Ahn JH; Lim Y
Bioorg Med Chem Lett; 2008 Jan; 18(2):661-4. PubMed ID: 18063365
[TBL] [Abstract][Full Text] [Related]
8. Molecular dynamic behavior and binding affinity of flavonoid analogues to the cyclin dependent kinase 6/cyclin D complex.
Khuntawee W; Rungrotmongkol T; Hannongbua S
J Chem Inf Model; 2012 Jan; 52(1):76-83. PubMed ID: 22172011
[TBL] [Abstract][Full Text] [Related]
9. Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7.
Chohan TA; Qian HY; Pan YL; Chen JZ
Mol Biosyst; 2016 Jan; 12(1):145-61. PubMed ID: 26565382
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues.
Ahn YM; Vogeti L; Liu CJ; Santhapuram HK; White JM; Vasandani V; Mitscher LA; Lushington GH; Hanson PR; Powell DR; Himes RH; Roby KF; Ye Q; Georg GI
Bioorg Med Chem; 2007 Jan; 15(2):702-13. PubMed ID: 17123821
[TBL] [Abstract][Full Text] [Related]
11. A computational model of binding thermodynamics: the design of cyclin-dependent kinase 2 inhibitors.
Sims PA; Wong CF; McCammon JA
J Med Chem; 2003 Jul; 46(15):3314-25. PubMed ID: 12852762
[TBL] [Abstract][Full Text] [Related]
12. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4.
Park H; Yeom MS; Lee S
Chembiochem; 2004 Dec; 5(12):1662-72. PubMed ID: 15505811
[TBL] [Abstract][Full Text] [Related]
13. Computational study of the interactions between guanine derivatives and cyclin-dependent kinase 2 (CDK2) by CoMFA and QM/MM.
Alzate-Morales J; Caballero J
J Chem Inf Model; 2010 Jan; 50(1):110-22. PubMed ID: 20030297
[TBL] [Abstract][Full Text] [Related]
14. Role of phosphorylated Thr160 for the activation of the CDK2/Cyclin A complex.
De Vivo M; Cavalli A; Bottegoni G; Carloni P; Recanatini M
Proteins; 2006 Jan; 62(1):89-98. PubMed ID: 16292742
[TBL] [Abstract][Full Text] [Related]
15. [Simulation of kinase CDK2-cyclin A by the molecular dynamics method: effect of Gly16-->Ser16 and Arg274-->Gln274 substitutions on conformation of a kinase subunit].
Kholmurodov KhT; Koltovaia NA
Biofizika; 2009; 54(6):999-1004. PubMed ID: 20067177
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol.
Carlson B; Lahusen T; Singh S; Loaiza-Perez A; Worland PJ; Pestell R; Albanese C; Sausville EA; Senderowicz AM
Cancer Res; 1999 Sep; 59(18):4634-41. PubMed ID: 10493518
[TBL] [Abstract][Full Text] [Related]
17. Fusion of Structure and Ligand Based Methods for Identification of Novel CDK2 Inhibitors.
Mahajan P; Chashoo G; Gupta M; Kumar A; Singh PP; Nargotra A
J Chem Inf Model; 2017 Aug; 57(8):1957-1969. PubMed ID: 28723151
[TBL] [Abstract][Full Text] [Related]
18. [Molecular dynamics modeling of the substitution of serine for the conservative glycine in the G loop in the yeast cdc28-srm mutant using the crystalline lattice of human kinase CDK2].
Kholmurodov KhT; Kretov DA; Gerasimova AS; Koltovaia NA
Biofizika; 2006; 51(4):679-91. PubMed ID: 16909847
[TBL] [Abstract][Full Text] [Related]
19. Investigating the Inhibitory Effect of Wortmannin in the Hotspot Mutation at Codon 1047 of PIK3CA Kinase Domain: A Molecular Docking and Molecular Dynamics Approach.
Kumar DT; Doss CG
Adv Protein Chem Struct Biol; 2016; 102():267-97. PubMed ID: 26827608
[TBL] [Abstract][Full Text] [Related]
20. Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells.
Motwani M; Li X; Schwartz GK
Clin Cancer Res; 2000 Mar; 6(3):924-32. PubMed ID: 10741717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
